Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VH4770359 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The AEs are graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria where grades are defined based on numeric criteria as follows Grade 3: severe symptoms; Grade 4: potentially life-threatening. A higher grade indicates greater severity.
| Arm | Type | Description |
|---|---|---|
| Part A: VH4770359 SAD group | EXPERIMENTAL | Healthy participants will receive a single dose of VH4770359 on Day 1. Up to 7 cohorts will receive single ascending doses (SAD). |
| Part A: Placebo SAD group | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of Placebo on Day 1. |
| Part B: VH4770359 MAD group | EXPERIMENTAL | Healthy participants will receive 14 daily repeat doses of VH4770359 from Day 1 to Day 14. Up to 4 cohorts will receive multiple ascending doses (MAD). |
| Part B: Placebo MAD group | PLACEBO_COMPARATOR | Healthy participants will receive 14 daily repeat doses of Placebo from Day 1 to Day 14. |
| Part B: VH4770359 MAD Drug-Drug Interaction (DDI) group | EXPERIMENTAL | Healthy participants will receive 14 daily repeat doses of VH4770359 from Day 1 to Day 14. Participants will also receive 2 mg Midazolam on Days -1, Day 1 and Day 14. |
| Part B: Placebo MAD DDI group | PLACEBO_COMPARATOR | Healthy participants will receive 14 daily repeat doses of Placebo from Day 1 to Day 14. Participants will also receive 2 mg Midazolam on Days -1, Day 1 and Day 14. |
| Name | Type | Description |
|---|---|---|
| VH4770359 | DRUG | Participants will receive the assigned dose formulation of VH4770359 orally. |
| Placebo | DRUG | Participants will receive placebo to match the VH4770359 dose formulation. |
| Midazolam | DRUG | Participants receive 2 mg Midazolam on Days -1, Day 1 and Day 14. |
Inclusion Criteria: 1. 18 to 55 years old 2. BMI 18.5-37.0 kg/m2 3. Male participants must adhere to contraception requirements or abstinence, and female participants must not be pregnant/breastfeeding and be of non-childbearing potential. Exclusion Criteria: 1. Participants with significant medi...
Top 20 of 28 competitors
VH4770359 is an investigational small molecule being developed for the treatment of HIV Infections. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy participants to evaluate its safety and pharmacokinetics.
The molecular target of VH4770359 has not been disclosed in available information. As a small molecule in development for HIV Infections, its specific mechanism of action is not publicly detailed at this time.
VH4770359 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to investigate the drug's safety and pharmacokinetic profile in healthy participants.
VH4770359 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is recruiting healthy participants to assess the safety and pharmacokinetics of the drug.
VH4770359 is being studied in a Phase 1 clinical trial with the identifier NCT07525544. The trial, titled 'A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants,' is recruiting 214 participants in the United States. It is a randomized, double-blind, placebo-controlled study.